Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights […]
Eluminex Biosciences’ Acquisition of Zuretinol Acetate Assets from Retinagenix
Qilu Pharmaceutical’s Licensing Agreement and Partnership with Arbutus Biopharma Corporation
Goodwin Procter advised Qilu Pharmaceutical on the deal. Qilu Pharmaceutical, one of the leading pharmaceutical companies in China (“Qilu”), announced its exclusive licensing agreement and strategic partnership […]
MorphoSys’ $1.7 Billion Acquisition of Constellation Pharmaceuticals
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty […]
Amryt Pharma’s Acquisition of Chiasma
Goodwin Procter LLP advised Chiasma, Inc. on the deal. Chiasma, Inc. (Nasdaq: CHMA) announced its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: […]